Well if you are considering it you might have to wait a year or two for clinical trial results and commercial approval. Most likely it will result in a partnership deal with an established player like Edwards.
But from a technical point of view, it ticks an awful lot of boxes. If the trial results bear this out it's probably going to be irresistible to someone.
Anteris Channel 9 Interview 2022, page-30
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.86 |
Change
0.010(0.05%) |
Mkt cap ! $362.3M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.86 | $28.93K | 1.528K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $18.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.20 | 220 | 1 |
View Market Depth
| Last trade - 10.16am 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.02 |
Change
0.010 ( 0.96 %) |
||||
| Open | High | Low | Volume | ||
| $19.02 | $19.02 | $19.02 | 52 | ||
| Last updated 10.04am 28/05/2024 ? | |||||
| AVR (ASX) Chart |